Evidence map›Paper›PMID 41724842›Full record

ReviewArchives of microbiology2026

CRISPR/Cas systems in fungal biotechnology: advancing high-value metabolite synthesis for industrial and food security applications.

Uttam Kumar Jana, Praveen Bawankar, Pranshi Gupta, Naveen Kango

Abstract readReview
PubMed Publisher
In one paragraph

Review in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Uttam Kumar Jana *CSIR-National Institute of Science Communication and Policy Research (NIScPR), New Delhi, 110012, India. u.jana@csir.res.in.
Praveen Bawankar *Department of Microbiology, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar, MP, 470003, India. praveenbawankar@gmail.com.
Pranshi GuptaDepartment of Microbiology, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar, MP, 470003, India.
Naveen KangoDepartment of Microbiology, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar, MP, 470003, India. nkango@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fungi serve as pivotal industrial platforms to produce essential compounds from pharmaceuticals like antibiotics and statins to diverse enzymes, organic acids and nutraceuticals. Fungi drive innovation across the medical, food and biofuel sectors through the synthesis of specialized pigments, flavors and bioactive molecules. Despite this potential, the development of efficient genetic toolkits has historically been slowed by low homologous recombination rates and biological complexity of diverse fungal taxa. The adaptation of CRISPR/Cas technologies including Cas9, Cas12a (Cpf1), and base editing has recently bypassed these bottlenecks and offers record precision in fungal genome engineering. This review provides a detailed analysis of current mechanistic approaches such as the use of ribonucleoprotein (RNP) complexes and specialized promoters for guide RNA expression. We have explored how these tools enable the multiplexed editing of genes and the fine-tuning of transcriptional modulation (i.e. CRISPR inactivation/activation) to redirect target metabolites for high industrial output by optimizing fungal physiology. Furthermore, the integration of CRISPR-based biosensors for the rapid, high-sensitivity detection of fungal pathogens, highlighting the dual role of these technologies in both production and food security has also been discussed.

Indexed as

BiotechnologyCRISPR-Cas SystemsFungiIndustrial MicrobiologyFood SecurityGene EditingMetabolic EngineeringCas12aCas9CRISPRFilamentous fungiGene editingTranscriptional modulation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.